Enhertu designated gastric cancer BTD
11 May 2020 07:00 BST Enhertu granted Breakthrough Therapy Designationin the US for HER2-positive metastatic gastric cancer Second US Breakthrough Therapy Designation for Enhertu AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab. Gastric cancer is the third leading